Abstract 1157P
Background
Recent studies indicate an association between immunosuppressive medication for immune-related adverse events (irAEs) and impaired survival. Whether this is related to corticosteroids or second-line immunosuppressants (IS) is unknown. We assessed the association of immunosuppressive regimens with survival in patients with melanoma.
Methods
Patients with advanced melanoma who received IS for irAEs induced by first-line anti-PD-1+/-anti-CTLA-4 were included from 11 Dutch and Belgian hospitals. Associations of cumulative and peak doses of corticosteroids and use of second-line IS with progression free survival (PFS) from start of IS and overall survival (OS) since immune checkpoint inhibitor (ICI) initiation were assessed using multivariable Cox regression. Analyses were adjusted for sex, age, stage, performance status, LDH, ICI type and irAE type.
Results
Among 382 patients with irAEs, 255 had IPI+NIVO-induced irAEs and 127 had anti-PD-1-monotherapy-induced irAEs. 268 patients received only corticosteroids; 113 patients additionally received second-line IS. High peak corticosteroid dose was associated with worse PFS (HR 1.47 95%CI 1.00-2.16) and OS (HR 2.17 95%CI 1.49-3.16). Cumulative corticosteroid dose was not associated with PFS or OS (Table). Use of second-line IS was associated with worse PFS (HR 1.57 95%CI 1.04-2.38); for OS, this was the case when correction for cumulative corticosteroid dose (HR 1.57 95%CI 1.06-2.33), but not when correcting for peak corticosteroid dose (HR 1.25 95%CI 0.84-1.85). Subgroup analyses will be presented. Table: 1157P
Association of immunosuppressive irAE management with survival
PFS HR (95%CI) since immunosuppression | OS HR (95%CI) since ICI | |
Univariable | ||
Steroid peak dose (per 100mg) | 1.90 (1.39-2.61) | 1.89 (1.39-2.57) |
Steroid cumulative dose (per 1000mg) | 1.06 (1.00-1.12) | 0.95 (0.90-1.01) |
2nd-line IS | 1.83 (1.32-2.52) | 1.43 (1.04-1.97) |
Multivariable including steroid peak dose and 2nd-line IS | ||
Steroid peak dose (per 100mg) | 1.47 (1.00-2.16) | 2.17 (1.49-3.16) |
2nd-line IS | 1.57 (1.04-2.38) | 1.25 (0.84-1.85) |
Multivariable including steroid cumulative dose and 2nd-line IS | ||
Steroid cumulative dose (per 1000mg) | 1.01 (0.94-1.08) | 0.95 (0.89-1.02) |
2nd-line IS | 1.64 (1.09-2.47) | 1.57 (1.06-2.33) |
Conclusions
Our data suggest that use of second-line immunosuppressants and high peak corticosteroid dose are associated with impaired survival among patients requiring IS for irAEs, while there is no association between cumulative corticosteroid dose and survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University Medical Center Utrecht.
Funding
Has not received any funding.
Disclosure
G.A.P. Hospers: Financial Interests, Institutional, Advisory Board: Amgen, Bristol Myers Squibb, Roche, Merck Sharp & Dohme, Pfizer, Novartis, Sanofi, Pierre Fabre; Financial Interests, Institutional, Research Funding: Bristol Myers Squibb, Seerave. M.J.B. Aarts: Financial Interests, Institutional, Advisory Board: Amgen, Bristol Myers Squibb, Novartis, Merck Sharp & Dohme, Merck-Pfizer, Pierre Fabre, Sanofi, Astellas, Bayer; Financial Interests, Institutional, Research Funding: Merck-Pfizer. J.B.A.G. Haanen: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Achilles Therapeutics, Ipsen, Merck Sharp & Dohme, Merck Serono, Pfizer, Molecular Partners, Novartis, Roche, Sanofi, Third Rock Venture, Iovance Biotherapeutics; Financial Interests, Institutional, Advisory Board, SAB member: BioNTech, Immunocore, Gadeta, Instil Bio, PokeAcel, T-Knife; Financial Interests, Personal, Advisory Board, SAB member: Neogene Therapeutics, Scenic; Financial Interests, Personal, Stocks/Shares: Neogene Therapeutics; Financial Interests, Institutional, Research Grant: Bristol Myers Squibb, BioNTech US, Merck Sharp & Dohme, Amgen, Novartis, Asher Bio; Non-Financial Interests, Member: ASCO, AACR, SITC; Other, Editorial Board ESMO Open: ESMO; Other, Editor-in-Chief IOTECH: ESMO; Other, Editorial Board: Kidney Cancer. E. Kapiteijn: Financial Interests, Institutional, Advisory Board: BMS, Novartis, Pierre Fabre, Merck, Delcath, Bayer, Lilly; Financial Interests, Institutional, Coordinating PI: BMS, Pierre Fabre, Delcath. M. Labots: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Janssen-Cilag BV. A.A.M. Van der Veldt: Financial Interests, Institutional, Advisory Board: Bristol Myers Squibb, Merck Sharp & Dohme, Sanofi, Pfizer, Novartis, Roche, Eisai, Merck, Pierre Fabre, Ipsen. S. Aspeslagh: Financial Interests, Institutional, Advisory Board: Merck Sharp & Dohme, Sanofi, Roche, Bristol Myers Squibb, Pfizer, Ipsen, Galapagos. K.P.M. Suijkerbuijk: Financial Interests, Institutional, Advisory Board: Novartis, BMS, AbbVie, Pierre Fabre, MSD; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Grant: Novartis, TigaTx. All other authors have declared no conflicts of interest.
Resources from the same session
1149P - Prognosis for patients with metastatic Merkel cell carcinoma with a complete response on avelumab treatment
Presenter: Lisanne Zijlker
Session: Poster session 13
1150P - Transforming growth factor-beta-1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in advanced basal cell carcinoma
Presenter: Bernardo Rapoport
Session: Poster session 13
1151P - Characteristics and treatment outcomes in cutaneous adnexal carcinomas
Presenter: Adam Rock
Session: Poster session 13
1152P - Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhibitors (ICI)
Presenter: Fernanda Costa Svedman
Session: Poster session 13
1153P - Incidence and characteristics of immunotherapy related adrenal insufficiency in a monocenter, pan-cancer cohort of 4314 patients
Presenter: Minke Lucas
Session: Poster session 13
1154P - Thromboembolic events in patients with melanoma receiving immune checkpoint inhibitors: Incidence and risk factors
Presenter: Daan van Dorst
Session: Poster session 13
1155P - Application of novel machine learning to predict immunotherapy related toxicities for metastatic melanoma patients from baseline 18F-FDG PET/CT scans
Presenter: Roslyn Francis
Session: Poster session 13
1156P - Immune-related adverse events in a nationwide cohort of melanoma patients treated with adjuvant anti-PD1: Seasonal variation and association with outcome
Presenter: Eva Ellebæk
Session: Poster session 13
1158P - Association of corticosteroid (CS) exposure with treatment failure in patients (pts) with advanced melanoma treated with immune checkpoint inhibitors (ICIs)
Presenter: Ha Mo Linh Le
Session: Poster session 13
1159P - Characterization of melanoma of unknown primary in the era of immunotherapy and targeted therapy in Spain: Results from the prospective real-world study GEM 1801
Presenter: Pablo Cerezuela-Fuentes
Session: Poster session 13